TickerFacts.

Anbio Biotechnology (NNNN): Shareholders' Equity

Annual figures by period end, from SEC filings.

$30.16M
As of 2025-12-31
+33.9%
3-year compound annual growth
2022-12-31: $12.55M2023-12-31: $14.82M2024-12-31: $17.19M2025-12-31: $30.16M$30.16M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$30.16M+75.4%2026-04-07, Balance as of period end
2024-12-31$17.19M+16.0%2026-04-07, Balance as of period end
2023-12-31$14.82M+18.1%2026-04-07, Balance as of period end
2022-12-31$12.55Mn/a2025-04-28, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Anbio Biotechnology (NNNN)2025-12-31$30.16M+75.4%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m
Biomerica Inc (BMRA)2026-05-31$2.63M-35.9%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$31.46Mn/m
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Volitionrx Ltd (VNRX)2025-12-31-$34.25Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31$527.16M-29.4%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗